In our previous study, we found that glioma patients with high expression of B7-H4 had no survival benefits from DC vaccine, one of the main forms of immunotherapies, whereas others having low expression benefited with improved survival time from immunotherapy [22]. The gene discussed is VTCN1; the disease is glioma.